Definitive Contract 75N93025C00040

Award Date 9/29/25
Potential Completion Date 9/29/26
Potential Value $500K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Durham, NC 27701, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a $300,000.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the U.S. Department of Health and Human Services, to Ividence Inc., a for-profit small business located in Hockessin, Delaware. The contract is for a Phase I Small Business Innovation Research (SBIR) program award, which is part of a larger SBIR solicitation from NIAID and the Centers for Disease Control and Prevention (CDC) covering a wide range...
This is a $299,986 firm fixed-price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Big Eye Diagnostics Inc., a small business manufacturer, for the development and validation of novel diagnostic biomarkers for malaria and select neglected tropical diseases. The contract is part of NIAID's Small Business Innovation Research (SBIR) program, which provides funding to small businesses for innovative research and development. The objective is to create rapid,...
This is a $600,000.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Glycoscientific, L.L.C., a small business concern. The contract is for the development of reagents for immunologic analysis of non-mammalian and underrepresented mammalian models, under the Small Business Innovation Research (SBIR) program. The contract has a period of performance ending on November 23,...
<p>This is a fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the Department of Health and Human Services. The contract, valued at $4,500.00, is for &quot;DRUGS AND BIOLOGICALS&quot; with an ultimate completion date of January 6, 2010. The contract was awarded to Ebioscience, Inc., a for-profit organization, on December 7, 2009. This contract does not have a set-aside designation.</p>
This is a $599,234 firm fixed price contract awarded by the Department of Health and Human Services National Institutes of Health National Institute of Allergy and Infectious Diseases (NIAID) to Celdara Medical, a small business biotechnology company, under the Small Business Innovation Research (SBIR) program. The contract is for research to discover parasite-derived tolerogenic adjuvants, which could potentially be used in new vaccine development. Celdara Medical conducts research and...
This is a $300,000 Firm Fixed Price contract awarded by the Department of Health and Human Services' National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Vitruvian Bio, LLC, a small disadvantaged woman-owned business. The contract is for a Small Business Innovation Research (SBIR) Phase I project to be completed by June 30, 2023. The award is associated with a larger SBIR solicitation that sought innovative research proposals from small businesses to...
This federal contract award, valued at $299,659.00, was granted to Big Eye Diagnostics Inc., a small business manufacturer of goods, by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH). The contract is part of the Small Business Innovation Research (SBIR) program and is a Definitive Contract with a Firm Fixed Price pricing type. The contract is for the development of an &quot;easy-to-use, low-cost triplex RDT for the...
This $1,797,717.00 Small Business Innovation Research (SBIR) Phase I contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency under the National Institutes of Health (NIH), to Intralytix Inc., a biotechnology company specializing in bacteriophage-based products. The contract is for the development of a &quot;Universal, Scalable Artificial Intelligence-Based Platform for Manufacturing High Titer Biopharmaceuticals&quot;, which aligns with...
This is a firm fixed-price purchase order contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), an agency within the Department of Health and Human Services, to Ebioscience, Inc. for &quot;DRUGS AND BIOLOGICALS&quot; with a ceiling value of $3,339.05. The ultimate completion date for this contract is May 4, 2012. The contract is not designated as a set-aside. Ebioscience, Inc. is a for-profit organization and a subsidiary of the parent company Affymetrix, Inc.,...
This is a $544,000.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is for biomedical (applied/exploratory) research and does not have a set-aside designation. Through this contract, Southern Research Institute is providing a range of services, including drug discovery and...

This is a $499,825 firm-fixed-price federal contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to Eydis Bio, Inc., a small business concern. The contract is for the performance of a structure-activity relationship (SAR) analysis, molecular binding and metabolism studies of the lead scaffold (HS-176) to guide the development of more potent and drug-like analogs, as well as prioritization of lead analogs through in vitro efficacy screening. This contract was awarded under the Small Business Innovation Research (SBIR) program, which is set aside for small businesses. Eydis Bio, Inc. is a pharmaceutical research and development company focused on developing small molecule inhibitors targeting TAK1 (TGFv-activated kinase 1) for various complex medical conditions, including neurodegenerative diseases, inflammatory disorders, and pain management.

Generated 10/5/25, 12:58 AM